TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34593311

Group type: EXPERIMENTAL
Intervention: NHFOV therapy
Number of subjects: 150

Group type: COMPARATOR
Intervention: NIPPV therapy
Number of subjects: 150
Study: 34515589

Group type: EXPERIMENTAL
Intervention: Seated position
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Supine position
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Standing position
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Test-retest reliability in supine position
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Test-retest reliability in seated position
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Test-retest reliability in standing position
Number of subjects: 42
Study: 34299895

Group type: EXPERIMENTAL
Intervention: Dynamically tailored exergame (based on an accelerometer sensor integrated in a T-shirt)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Non-tailored exergame
Number of subjects: 94
Study: 33093947

Group type: EXPERIMENTAL
Intervention: Acalabrutinib in combination with R-CHOP
Number of subjects: 39
Study: 33168602

Group type: EXPERIMENTAL
Intervention: Tacrolimus (0.05 mg/kg twice-daily) plus low-dose corticosteroid (0.5 mg/kg prednisolone once-daily)
Number of subjects: 144

Group type: COMPARATOR
Intervention: High-dose corticosteroid (1 mg/kg prednisolone once-daily)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Maintenance tacrolimus (3-8 ng/ml) plus tapered steroid
Number of subjects: 144

Group type: COMPARATOR
Intervention: Tapered steroid alone
Number of subjects: 144
Study: 36098857

Group type: EXPERIMENTAL
Intervention: Arbuscular mycorrhizal fungi (Glomus mosseae)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Cadmium concentrations (0, 10, 25, 50, 75 and 100 mg kg‐1)
Number of subjects: 3
Study: 32387721

Group type: EXPERIMENTAL
Intervention: Episodic memory ability
Number of subjects: 205

Group type: COMPARATOR
Intervention: Working memory capacity
Number of subjects: 205
Study: 34986782

Group type: EXPERIMENTAL
Intervention: Experimental group received 12-15 hours of training for providers.
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control providers received six webinars on early development.
Number of subjects: 34
Study: 34105881

Group type: EXPERIMENTAL
Intervention: severe ETW (s-ETW, lemon juice/pH:2.5/4.25%wt/vol citric acid)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: moderate ETW (m-ETW, grapefruit juice/pH:3.5/1.03%wt/vol citric acid)
Number of subjects: 20

Group type: COMPARATOR
Intervention: non-ETW (water)
Number of subjects: 20
Study: 32498534

Group type: EXPERIMENTAL
Intervention: Dexrazoxane
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control (without dexrazoxane)
Number of subjects: 64
Study: 33155711

Group type: EXPERIMENTAL
Intervention: SMS intervention (n=230)
Number of subjects: 462

Group type: COMPARATOR
Intervention: Treatment as usual (TAU) (n=232)
Number of subjects: 462

Group type: EXPERIMENTAL
Intervention: SMS intervention
Number of subjects: 462

Group type: COMPARATOR
Intervention: TAU
Number of subjects: 462
Study: 34941300

Group type: EXPERIMENTAL
Intervention: Taekwondo intervention (11-week beginners' course)
Number of subjects: 240
Study: 35051323

Group type: EXPERIMENTAL
Intervention: Children's powered toothbrush
Number of subjects: 55

Group type: COMPARATOR
Intervention: Children's manual toothbrush
Number of subjects: 55
Study: 32798490

Group type: EXPERIMENTAL
Intervention: Atezolizumab, vemurafenib, and cobimetinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 35550672

Group type: EXPERIMENTAL
Intervention: Probiotic mixture containing four strains of Bifidobacterium species and one Lacticaseibacillus strain, administered daily, dosage not specified, duration not specified.
Number of subjects: 0
Study: 32443684

Group type: EXPERIMENTAL
Intervention: Formula containing BMOS
Number of subjects: 203

Group type: COMPARATOR
Intervention: Control formula
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: All formula groups
Number of subjects: 203
Study: 35533640

Group type: EXPERIMENTAL
Intervention: Salinity-resistant ecotypes (e.g., 'AE5')
Number of subjects: 6

Group type: COMPARATOR
Intervention: Salinity-susceptible ecotypes (e.g., 'AE3')
Number of subjects: 6
Study: 34508672

Group type: EXPERIMENTAL
Intervention: Anodal tDCS
Number of subjects: 15

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 15
Study: 35979056

Group type: EXPERIMENTAL
Intervention: Nurse-led health education based on the knowledge, belief, and practice model
Number of subjects: 60
Study: 32859933

Group type: EXPERIMENTAL
Intervention: Faecal microbiota transplantation (FMT) from healthy donors
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo FMT (vehicle only)
Number of subjects: 20
Study: 35772250

Group type: EXPERIMENTAL
Intervention: EEG-guided anesthesia (EEG-G)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: EEG-guided anesthesia (EEG-G) and Standard care (SC)
Number of subjects: 200
Study: 34269090

Group type: EXPERIMENTAL
Intervention: Hematology/oncology drugs with pediatric label changes
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Hematology/oncology drugs with pediatric indications
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Hematology/oncology drugs that failed to receive pediatric indications
Number of subjects: 49
Study: 32473356

Group type: EXPERIMENTAL
Intervention: Ticagrelor 180 mg loading dose
Number of subjects: 1900

Group type: COMPARATOR
Intervention: Clopidogrel (300 or 600 mg loading dose)
Number of subjects: 1900

Group type: EXPERIMENTAL
Intervention: Ticagrelor 90 mg twice daily for 30 days
Number of subjects: 1900

Group type: COMPARATOR
Intervention: Clopidogrel 75 mg once daily for 30 days
Number of subjects: 1900
Study: 34961496

Group type: EXPERIMENTAL
Intervention: Educational intervention based on health belief model
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 200
Study: 32067096

Group type: EXPERIMENTAL
Intervention: Ultra-high-fidelity (UHF) VR simulation training
Number of subjects: 24

Group type: COMPARATOR
Intervention: Conventional, screen-based VR simulation training (cVR)
Number of subjects: 24
Study: 35275761

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 16
Study: 33581295

Group type: EXPERIMENTAL
Intervention: Multisite injection therapy (2 mL of triamcinolone acetonide, 4 mL of bupivacaine, and 34 mL of saline solution)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Single injection therapy (1 mL of triamcinolone acetonide and 2 mL of bupivacaine)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Multisite injection therapy
Number of subjects: 76

Group type: COMPARATOR
Intervention: Single injection therapy
Number of subjects: 76
Study: 35413116

Group type: EXPERIMENTAL
Intervention: Idasanutlin 300 mg plus cytarabine 1 g/m2 IV on days 1 to 5 of 28-day cycles
Number of subjects: 447

Group type: COMPARATOR
Intervention: Placebo plus cytarabine 1 g/m2 IV on days 1 to 5 of 28-day cycles
Number of subjects: 447

Group type: EXPERIMENTAL
Intervention: Idasanutlin plus cytarabine
Number of subjects: 447

Group type: COMPARATOR
Intervention: Placebo plus cytarabine
Number of subjects: 447
Study: 33650303

Group type: EXPERIMENTAL
Intervention: Arthroscopic partial meniscectomy (APM)
Number of subjects: 287

Group type: COMPARATOR
Intervention: Physical therapy (PT)
Number of subjects: 287
Study: 36302345

Group type: EXPERIMENTAL
Intervention: Targeted Lung Denervation (TLD)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham bronchoscopy
Number of subjects: 20
Study: 34941132

Group type: EXPERIMENTAL
Intervention: Tetracycline-containing regimen
Number of subjects: 284

Group type: COMPARATOR
Intervention: Furazolidone-containing regimen
Number of subjects: 284
Study: 34535176

Group type: COMPARATOR
Intervention: Cisplatin intravenous drip (Group A)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Capecitabine on the basis of cisplatin (Group B)
Number of subjects: 136
Study: 32023995

Group type: EXPERIMENTAL
Intervention: Active and Healthy Kids program (120 min/week of physically active learning and 25 min/week of physical active breaks)
Number of subjects: 644

Group type: COMPARATOR
Intervention: Control group (9 schools, 135 min/week of physical education)
Number of subjects: 644

Group type: EXPERIMENTAL
Intervention: Active and Healthy Kids program (for girls)
Number of subjects: 644
Study: 36308441

Group type: EXPERIMENTAL
Intervention: Calmangafodipir (CaM) 5 μmol/kg
Number of subjects: 592

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 592
Study: 33341226

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) with usual care (UC)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 108
Study: 32692493

Group type: EXPERIMENTAL
Intervention: Methylene blue (MB) administration as a bolus followed by continuous infusion
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Methylene blue (MB) administration
Number of subjects: 7
Study: 35393916

Group type: EXPERIMENTAL
Intervention: Virtual reality dementia tour
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Physical-based dementia tour
Number of subjects: 41

Group type: COMPARATOR
Intervention: Reading strengths-focused case studies
Number of subjects: 41
Study: 33839788

Group type: EXPERIMENTAL
Intervention: Combination exercise (COMB)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (AEX)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Resistance exercise (REX)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 160
Study: 32206903

Group type: EXPERIMENTAL
Intervention: Generic exenatide
Number of subjects: 240

Group type: COMPARATOR
Intervention: Branded exenatide
Number of subjects: 240
Study: 33900803

Group type: EXPERIMENTAL
Intervention: Oral Chemotherapy Management Program (OCMP)
Number of subjects: 0
Study: 32209975

Group type: EXPERIMENTAL
Intervention: Tomographic-biomechanical parameter (TBI)
Number of subjects: 1295

Group type: COMPARATOR
Intervention: PRFI-Pentacam Random Forest Index
Number of subjects: 1295

Group type: COMPARATOR
Intervention: BAD-D-Belin-Ambrosio D value
Number of subjects: 1295

Group type: COMPARATOR
Intervention: CBI-corneal biomechanical index
Number of subjects: 1295

Group type: COMPARATOR
Intervention: IS Abs-Inferior-superior value
Number of subjects: 1295

Group type: COMPARATOR
Intervention: PRFI
Number of subjects: 1295

Group type: COMPARATOR
Intervention: BAD-D
Number of subjects: 1295

Group type: COMPARATOR
Intervention: CBI
Number of subjects: 1295

Group type: COMPARATOR
Intervention: IS Abs
Number of subjects: 1295
Study: 34791107

Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP; 400 mg loading dose at Weeks 0/2/4 then 200/400 mg every 2/4 weeks)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 136
Study: 33647588

Group type: EXPERIMENTAL
Intervention: Higher working memory function
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Stressful moments and presence of peers and alcohol cues
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Biological sex differences
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Working memory function
Number of subjects: 86
Study: 32592657

Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 13981

Group type: COMPARATOR
Intervention: Non-statin
Number of subjects: 13981
Study: 34119569

Group type: EXPERIMENTAL
Intervention: Sevoflurane anesthesia (Group S)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Desflurane anesthesia (Group D)
Number of subjects: 60
Study: 32197503

Group type: EXPERIMENTAL
Intervention: Sensor-based system for monitoring rehabilitation progress after TKR
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cybex isokinetic dynamometer (control)
Number of subjects: 0
Study: 33711638

Group type: EXPERIMENTAL
Intervention: Testosterone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 32415792

Group type: EXPERIMENTAL
Intervention: Lower educational level of the head of household (proxy for poverty)
Number of subjects: 941

Group type: EXPERIMENTAL
Intervention: Greater number of children per room in the household
Number of subjects: 941

Group type: EXPERIMENTAL
Intervention: Body mass index
Number of subjects: 941
Study: 35872996

Group type: EXPERIMENTAL
Intervention: Multiphase prediction models developed from a retrospective cohort database
Number of subjects: 17445

Group type: EXPERIMENTAL
Intervention: Smartphone-based app 'OHSS monitor'
Number of subjects: 17445
Study: 34651535

Group type: EXPERIMENTAL
Intervention: NOMAC-E2
Number of subjects: 44559

Group type: COMPARATOR
Intervention: COC(LNG)
Number of subjects: 44559
Study: 36205248

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 10 mg daily for 45 days after hospital discharge
Number of subjects: 10000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10000
Study: 34105416

Group type: EXPERIMENTAL
Intervention: Listening to instrumental music before bed
Number of subjects: 249

Group type: COMPARATOR
Intervention: Listening to lyrical music before bed
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Persistent nighttime earworms
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Frontal slow oscillation activity
Number of subjects: 249
Study: 32697909

Group type: EXPERIMENTAL
Intervention: Fast randomized iteration method for full configuration interaction (FCI‐FRI) with initiator approximation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Semistochastic extension of FCI‐FRI
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New approach to sampling excitations
Number of subjects: 0
Study: 35646366

Group type: EXPERIMENTAL
Intervention: Night-simulating eyeglasses
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham eyeglasses
Number of subjects: 30

Group type: COMPARATOR
Intervention: Negative controls (non-cancer, disease-free individuals)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Positive controls (advanced cancer patients with disrupted circadian organization)
Number of subjects: 30
Study: 33863853

Group type: EXPERIMENTAL
Intervention: Resistance exercise
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Bike exercise
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Water-based exercise (WE)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control session
Number of subjects: 60
Study: 33189414

Group type: EXPERIMENTAL
Intervention: PROMUFRA program (multi-component exercise program, high-intensity resistance training combined with self-massage for myofascial release) for 12 weeks (2 d.wk-1)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: PROMUFRA program
Number of subjects: 50
Study: 34546614

Group type: EXPERIMENTAL
Intervention: L-PRP application onto the sutured fascia
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control (no L-PRP application)
Number of subjects: 33
Study: 32304829

Group type: EXPERIMENTAL
Intervention: Safety Planning Intervention (SPI) during jail detention plus post-release phone follow-up
Number of subjects: 800

Group type: COMPARATOR
Intervention: Enhanced Standard Care
Number of subjects: 800
Study: 34870852

Group type: EXPERIMENTAL
Intervention: Isoflurane sedation
Number of subjects: 66

Group type: COMPARATOR
Intervention: Propofol sedation
Number of subjects: 66
Study: 33410692

Group type: EXPERIMENTAL
Intervention: iCIPT2 (iterative configuration interaction with selection and second-order perturbation theory)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: iCIPT2
Number of subjects: 0
Study: 32242760

Group type: EXPERIMENTAL
Intervention: Video consent process
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interactive tablet 'app' consent process
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard brochure-based consent
Number of subjects: 0
Study: 34259849

Group type: EXPERIMENTAL
Intervention: Negative language in physician notes
Number of subjects: 507

Group type: EXPERIMENTAL
Intervention: Positive language in physician notes
Number of subjects: 507
Study: 33170863

Group type: EXPERIMENTAL
Intervention: DTG + FTC
Number of subjects: 187

Group type: COMPARATOR
Intervention: cART
Number of subjects: 187
Study: 35973906

Group type: EXPERIMENTAL
Intervention: Budesonide Oral Suspension
Number of subjects: 318

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 318
Study: 33725153

Group type: EXPERIMENTAL
Intervention: Fresh whole blood transfusion (FWBG)
Number of subjects: 65
Study: 32379992

Group type: EXPERIMENTAL
Intervention: Probiotic tablets containing Weissella cibaria CMU (1 × 10^8 CFU/g)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 92
Study: 36476623

Group type: EXPERIMENTAL
Intervention: Single-dose dalbavancin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Two-dose dalbavancin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparator antibiotic
Number of subjects: 0
Study: 33855218

Group type: COMPARATOR
Intervention: Eptinezumab
Number of subjects: 45
Study: 33373537

Group type: EXPERIMENTAL
Intervention: Integration algorithm using higher CDRS‐R item score
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: Follow-up assessments
Number of subjects: 439
Study: 33135364

Group type: EXPERIMENTAL
Intervention: Power of Food Scale
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Weight Efficacy Lifestyle Questionnaire
Number of subjects: 67
Study: 33586647

Group type: EXPERIMENTAL
Intervention: Left-sided taVNS
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Right-sided taVNS
Number of subjects: 82

Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 82
Study: 33705158

Group type: EXPERIMENTAL
Intervention: Enhanced Care (EC)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 204
Study: 32413383

Group type: EXPERIMENTAL
Intervention: Fluoride varnish
Number of subjects: 275

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 275
Study: 33808784

Group type: EXPERIMENTAL
Intervention: Bioavailable diosmin (μsmin® Plus) 450 mg tablet once daily for 8 weeks
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 34423374

Group type: EXPERIMENTAL
Intervention: Ticagrelor plus placebo
Number of subjects: 6835

Group type: COMPARATOR
Intervention: Ticagrelor plus aspirin
Number of subjects: 6835
Study: 32522163

Group type: EXPERIMENTAL
Intervention: ePRO symptom-report system
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: ePRO system
Number of subjects: 40
Study: 35984181

Group type: EXPERIMENTAL
Intervention: Navigated TKA
Number of subjects: 213

Group type: COMPARATOR
Intervention: Conventional TKA
Number of subjects: 213
Study: 34571263

Group type: EXPERIMENTAL
Intervention: Short arm (expected stay 7-10 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Long arm (expected stay 12-16 days)
Number of subjects: 0
Study: 32867992

Group type: EXPERIMENTAL
Intervention: CWE (basal diet + 1,000 mg/kg chestnut tannins)
Number of subjects: 168
Study: 35227777

Group type: EXPERIMENTAL
Intervention: Higher induction regimen (adalimumab 160 mg at weeks 0, 1, 2, and 3)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard induction regimen (adalimumab 160 mg at week 0 and 80 mg at week 2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 40 mg every week (ew) maintenance regimen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 40 mg every other week (eow) maintenance regimen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 40 mg ew maintenance regimen (integrated population)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 40 mg eow maintenance regimen (integrated population)
Number of subjects: 0
Study: 32275467

Group type: EXPERIMENTAL
Intervention: Capecitabine (3 cycles of capecitabine and docetaxel followed by 3 cycles of capecitabine, epirubicin, and cyclophosphamide)
Number of subjects: 585

Group type: COMPARATOR
Intervention: Control (3 cycles of docetaxel followed by 3 cycles of fluorouracil, epirubicin, and cyclophosphamide)
Number of subjects: 585

Group type: EXPERIMENTAL
Intervention: Capecitabine
Number of subjects: 585

Group type: COMPARATOR
Intervention: Control
Number of subjects: 585
Study: 32716040

Group type: EXPERIMENTAL
Intervention: Social media-based weight loss intervention (12 weeks, self-monitoring via Fitbits, participation in a private Facebook group)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Social media-based weight loss intervention
Number of subjects: 55
Study: 32756564

Group type: EXPERIMENTAL
Intervention: Hypohydration (1.9% body mass loss)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Rehydration protocol (heat tent and fluid replacement)
Number of subjects: 16
Study: 35690965

Group type: EXPERIMENTAL
Intervention: Gap balancer (GB) technique
Number of subjects: 94

Group type: COMPARATOR
Intervention: Measured resection (MR) technique
Number of subjects: 94
Study: 33072363

Group type: EXPERIMENTAL
Intervention: Person-centred and thriving-promoting intervention
Number of subjects: 341
Study: 35133549

Group type: EXPERIMENTAL
Intervention: Self-affirmation
Number of subjects: 144

Group type: COMPARATOR
Intervention: Control
Number of subjects: 144
Study: 34433855

Group type: EXPERIMENTAL
Intervention: Reaming at a diameter of 4.0 mm (Group 3) using RIA
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Reaming at a diameter of 1.5 mm (Group 1) using RIA
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Reaming at a diameter of 2.5 mm (Group 2) using RIA
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: All groups (1.5 mm, 2.5 mm, and 4.0 mm)
Number of subjects: 45
Study: 32939546

Group type: EXPERIMENTAL
Intervention: Ad26,ZEBOV (Ad26) and MVA-BN-Filo (MVA) vaccines
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Heterologous regimens (Ad26,MVA or MVA,Ad26)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Booster vaccination with Ad26 or MVA
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Homologous regimens (Ad26,Ad26)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Heterologous two-dose Ad26,MVA regimens
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Booster vaccination
Number of subjects: 164

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 164
Study: 34843406

Group type: EXPERIMENTAL
Intervention: Ro-CHOP (Romidepsin 12 mg/m² IV on days 1 and 8 of each 3-week cycle for six cycles)
Number of subjects: 421

Group type: COMPARATOR
Intervention: CHOP (Cyclophosphamide, doxorubicin, vincristine, and prednisone in 3-week cycles for six cycles)
Number of subjects: 421

Group type: EXPERIMENTAL
Intervention: Ro-CHOP
Number of subjects: 421

Group type: COMPARATOR
Intervention: CHOP
Number of subjects: 421
Study: 34098994

Group type: EXPERIMENTAL
Intervention: Real acupuncture treatment (20 sessions, 5 sessions per week)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham acupuncture treatment (20 sessions, 5 sessions per week)
Number of subjects: 60